Active Biotech AB - Interim report January - June 2017

(Thomson Reuters ONE) -



Second quarter in brief
* In April, the US Food and Drug Administration (FDA) granted Orphan Drug
Designation for tasquinimod for the treatment of multiple myeloma
* The primary clinical endpoint from the Phase III trial of laquinimod in RRMS
(CONCERTO study) was not met. The secondary endpoints (brain atrophy,
relapse rate and MRI-data) were achieved and in line with previous studies
* Out-licensing activities are continuing for tasquinimod, paquinimod and SILC

Events after the end of the period
* Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company
July 1, 2017
* In July, a patent application for the use of ANYARA in combination with PD-
1 inhibitors for the treatment of cancer was published on WIPO's (World
Intellectual Property Organization) website www.wipo.int

Financial summary
SEK M April-June Jan.-June Full-year

  2017 2016 2017 2016 2016
-------------------------------------------------------------------------------


Net sales 5.1 3.9 9.8 7.9 19.0

Operating loss -23.1 -14.5 -37.7 -30.6 -55.1

Loss for the period -24.4 -15.5 -40.2 -32.3 -59.6

Loss per share, before and after dilution -0.25 -0.17 -0.42 -0.36 -0.65
(SEK)

Cash and cash equivalents (at the end of     47.7 57.4 77.7
the period)



For further information, please contact:
  Helén Tuvesson, President & CEO Active Biotech AB
  Tel: +46 (0)46-19 21 56 (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Hans Kolam, CFO Tel: 046 (0)46-19 20 00

  Tel: +46 (0)46 19 20 44

The report is also available at www.activebiotech.com.

Active Biotech AB - Interim report January ? June 2017 :
http://hugin.info/1002/R/2126480/811875.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 10.08.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 556023
Anzahl Zeichen: 2681

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 209 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB - Interim report January - June 2017"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech